Open Access

Celecoxib induces adipogenic differentiation of hemangioma‑derived mesenchymal stem cells through the PPAR‑γ pathway in vitro and in vivo

  • Authors:
    • Yuan Wang
    • Liangliang Kong
    • Buhao Sun
    • Jie Cui
    • Weimin Shen
  • View Affiliations

  • Published online on: April 7, 2022     https://doi.org/10.3892/etm.2022.11303
  • Article Number: 375
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Infantile hemangioma (IH) is a benign tumor that produces a permanent scar or a mass of fibro‑fatty tissue after involution in 40‑80% of cases. Celecoxib is an inhibitor of cyclooxygenase‑2 (COX‑2), and can inhibit angiogenesis and fibrosis. The present study aimed to clarify whether celecoxib is able to induce tumor regression with minimal side effects. For that purpose, the regulation of celecoxib in the involution of IH was investigated in an IH model. Hemangioma‑derived mesenchymal stem cells (Hem‑MSCs) were isolated from proliferating specimens, and an IH model was established by injecting these cells into nude mice. Celecoxib was administered in vitro and in vivo. Oil Red O staining and reverse transcription‑quantitative‑PCR were used to detect the adipogenic differentiation of Hem‑MSCs. Histologic analysis and immunohistochemical staining of the tumor xenografts were performed to investigate the pathological evolution of the tumor. The results showed that celecoxib inhibited the proliferation and induced the adipogenic differentiation of Hem‑MSCs in vitro. In vivo, adipocytes were only present in the celecoxib group at week 4, while a larger number of fibroblasts and collagenous fibers could be observed in the basic fibroblast growth factor group. Therefore, celecoxib may be a potential agent used for IH treatment by inducing adipogenesis and inhibiting fibroblast formation.
View Figures
View References

Related Articles

Journal Cover

June-2022
Volume 23 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang Y, Kong L, Sun B, Cui J and Shen W: Celecoxib induces adipogenic differentiation of hemangioma‑derived mesenchymal stem cells through the PPAR‑γ pathway <em>in vitro</em> and <em>in vivo</em>. Exp Ther Med 23: 375, 2022
APA
Wang, Y., Kong, L., Sun, B., Cui, J., & Shen, W. (2022). Celecoxib induces adipogenic differentiation of hemangioma‑derived mesenchymal stem cells through the PPAR‑γ pathway <em>in vitro</em> and <em>in vivo</em>. Experimental and Therapeutic Medicine, 23, 375. https://doi.org/10.3892/etm.2022.11303
MLA
Wang, Y., Kong, L., Sun, B., Cui, J., Shen, W."Celecoxib induces adipogenic differentiation of hemangioma‑derived mesenchymal stem cells through the PPAR‑γ pathway <em>in vitro</em> and <em>in vivo</em>". Experimental and Therapeutic Medicine 23.6 (2022): 375.
Chicago
Wang, Y., Kong, L., Sun, B., Cui, J., Shen, W."Celecoxib induces adipogenic differentiation of hemangioma‑derived mesenchymal stem cells through the PPAR‑γ pathway <em>in vitro</em> and <em>in vivo</em>". Experimental and Therapeutic Medicine 23, no. 6 (2022): 375. https://doi.org/10.3892/etm.2022.11303